Important Information for Geron Corporation Investors: Rosen Law Firm Reminds of Upcoming Deadline
New York, NY – April 2, 2025
Rosen Law Firm, a global investor rights law firm, is reminding purchasers of Geron Corporation (NASDAQ: GERN) securities between February 28, 2024, and February 25, 2025, both dates inclusive (the “Class Period”), of the upcoming May 12, 2025, lead plaintiff deadline. If you purchased Geron securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
What is a Securities Class Action Lawsuit?
A securities class action lawsuit is a type of legal action that allows a large group of individuals or institutions to collectively sue a company (or its officers or directors) for damages caused by alleged violations of securities laws. In such a lawsuit, the lead plaintiff represents the interests of the entire class, and any compensation recovered is distributed among the class members.
Why is Rosen Law Firm Reminding Geron Investors of the Lead Plaintiff Deadline?
The lead plaintiff is a crucial role in a securities class action lawsuit. They are responsible for making significant decisions about the litigation, including whether to accept a settlement offer or proceed to trial. The deadline for Geron investors to apply to serve as the lead plaintiff is May 12, 2025.
What Happened to Geron Corporation During the Class Period?
Geron Corporation is a biotechnology company focused on developing therapies for aging and age-related diseases. During the Class Period, Geron reported disappointing clinical trial results for its lead product, GRN163L, which failed to meet its primary endpoints in a Phase 2b clinical trial for treating age-related muscle wasting. These results caused Geron’s stock price to decline substantially.
What Does This Mean for Geron Investors?
- If you purchased Geron securities during the Class Period and suffered losses as a result, you may be eligible to recover your damages through a securities class action lawsuit.
- The deadline to apply to serve as the lead plaintiff is May 12, 2025. If you wish to be a lead plaintiff, you must file a motion with the court before this deadline.
- Even if you are not able to serve as the lead plaintiff, you can still be a class member and potentially recover damages.
What Does This Mean for the World?
The failure of Geron’s clinical trial for GRN163L is a setback for the biotechnology industry and the field of aging research. However, it also underscores the importance of transparency and disclosure in the securities markets. Securities class action lawsuits help ensure that companies provide accurate and complete information to investors, which in turn promotes confidence in the markets and supports economic growth.
Conclusion
If you purchased Geron Corporation securities during the Class Period, you may be entitled to compensation through a securities class action lawsuit. The deadline to apply to serve as the lead plaintiff is May 12, 2025. Investors who wish to be a lead plaintiff must file a motion with the court before this deadline. Even if you are not able to serve as the lead plaintiff, you can still be a class member and potentially recover damages. The failure of Geron’s clinical trial for GRN163L is a reminder of the importance of transparency and disclosure in the securities markets, and securities class action lawsuits help ensure that companies provide accurate and complete information to investors.
